5WK0.F Aligos Therapeutics, Inc.
- Market cap
- EUR 13.7M
- P/E
- -
- P/B
- 2.05x
- ROE
- -547.2%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is 5WK0.F undervalued?
Graham numberThe Graham number of Aligos Therapeutics, Inc. cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Aligos Therapeutics, Inc. fundamental analysis
No fundamental analysis for Aligos Therapeutics, Inc. yet.
Aligos Therapeutics, Inc. stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Aligos Therapeutics, Inc.
Aligos Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapeutics to address unmet medical needs in liver and viral diseases. Its drug candidate, ALG-055009, a small molecule THR-ß agonist that is in the Phase 2a clinical trial for the treatment of metabolic dysfunction-associated steatohepatitis and obesity. The company also develops pevifoscorvir sodium, a capsid assembly modulator, which is in Phase 2 B clinical trial;…
Full company profileAligos Therapeutics, Inc. financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Aligos Therapeutics, Inc. annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|
| Income Statement | ||||||
| Revenue | 4.36M | 13.9M | 15.5M | 3.95M | 2.19M | 44.6M |
| Operating Income | -128M | -97.6M | -88.1M | -89.2M | -88.0M | -67.6M |
| EBITDA | - | -93.9M | -85.1M | -86.5M | -85.2M | -64.6M |
| Net Income | -128M | -96.0M | -87.7M | -131M | -24.2M | -61.9M |
| EPS | -75 | -56 | -29 | -34 | -3.92 | -9.90 |
| Balance Sheet | ||||||
| Total Assets | 235M | 147M | 152M | 70.1M | 88.5M | 47.2M |
| Total Liabilities | 50.6M | 42.8M | 59.4M | 99.1M | 35.0M | 35.9M |
| Shareholders' Equity | 185M | 104M | 92.1M | -29.0M | 53.5M | 11.3M |
| Cash & Short-term Investments | 187M | 81.3M | 136M | 37.0M | 18.3M | 31.1M |
| Cash Flow | ||||||
| Operating Cash Flow | -116M | -79.4M | -79.0M | -80.7M | -82.5M | -62.2M |
| Capital Expenditure | 892K | 943K | 19.0K | 130K | 437K | 263K |
| Free Cash Flow | -117M | -80.3M | -79.0M | -80.9M | -82.9M | -62.4M |
| Ratios | ||||||
| ROE | -69.5% | -92.4% | -95.2% | - | -45.2% | -547.2% |
| ROA | -54.5% | -65.5% | -57.9% | -187.2% | -27.3% | -131.1% |
| Net Profit Margin | -2,944.1% | -690.6% | -564.6% | -3,326.0% | -1,106.7% | -138.6% |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
Aligos Therapeutics, Inc. dividends
Aligos Therapeutics, Inc. has not paid dividends in the last 5 fiscal years.
Last stock split: 1:25 on Aug 19, 2024.
Who owns Aligos Therapeutics, Inc.
- Insiders 10.64%
- Institutions 42.89%
- Public & others 46.47%
- Shares outstanding 5.45M
- Free float 3.68M
Aligos Therapeutics, Inc. company profile
- Company name
- Aligos Therapeutics, Inc.
- Ticker
- 5WK0.F
- Exchange
- Frankfurt Exchange
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 82
- Fiscal year end
- December
- Address
- One Corporate Drive, South San Francisco, CA, United States, 94080
- Phone
- 800 466 6059
- Website
- aligos.com
About Aligos Therapeutics, Inc.
Aligos Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapeutics to address unmet medical needs in liver and viral diseases. Its drug candidate, ALG-055009, a small molecule THR-ß agonist that is in the Phase 2a clinical trial for the treatment of metabolic dysfunction-associated steatohepatitis and obesity. The company also develops pevifoscorvir sodium, a capsid assembly modulator, which is in Phase 2 B clinical trial; and ALG-097558, a small molecule ritonavir-free pan-coronavirus protease inhibitor which has completed a Phase 1 clinical trial for the treatment of coronavirus. The company has entered into license and research collaboration agreement with Emory University; and Katholieke Universiteit Leuven. Aligos Therapeutics, Inc. was incorporated in 2018 and is headquartered in South San Francisco, California.
Aligos Therapeutics, Inc. management
10- Dr. Lawrence M. Blatt MBA, Ph.D.CEO, President & Chairman of the Board · born 1962
- Ms. Lesley Ann Calhoun CPAExecutive VP, CFO & COO · born 1966
- Dr. Julian A. Symons DPHILExecutive VP & Chief Scientific Officer · born 1962
- Mr. Nikhil AnejaPrincipal Accounting Officer · born 1977
- Ms. Laura KavanaughVP & Head of Legal
- Ms. Kristina Engeseth M.B.A.Senior VP and Head of People & Culture
- Dr. Sushmita M. Chanda DABT, Ph.D.Executive Vice President & Chief Development Officer · born 1967
- Dr. David B. Smith Ph.D.Executive VP & Head of Chemical Operations
- Dr. Tse-I Lin Ph.D.Senior VP of Early Compound Development & Belgian Site Head
- Dr. Kieron Wesson Ph.D.Vice President & Head of Chemistry Manufacturing Controls